Skip to main content

Animations

MJFF Publications

5491 - 5500 of 8808 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2020
  • 2021
  • 2021
  • 2022
  • 2021
  • Summary Details
    RESTRICTED
    Title: A randomized clinical trial of burst vs. spaced physical therapy for Parkinsons disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.02.021
    Citation Count: 12
  • Summary Details
    OPEN
    Title: Impaired bed mobility in prediagnostic and de novo Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.04.007
    Citation Count: 4
  • Summary Details
    RESTRICTED
    Title: Subacute tremor and ataxia: Diligence in pursuit of a diagnosis
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.05.016
    Citation Count: 1
  • Summary Details
    RESTRICTED
    Title: Droxidopa reduces postural sway in Parkinson disease patients with orthostatic hypotension
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.05.002
    Citation Count: 3
  • Summary Details
    RESTRICTED
    Title: L-Dopa response, choreic dyskinesia, and dystonia in Perry syndrome
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.05.023
    Citation Count: 7
  • Summary Details
    OPEN
    Title: Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.002
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.024
    Citation Count: 66
  • Summary Details
    OPEN
    Title: Intracellular Thermometry to Study Protein Aggregation Related to Neurodegenerative Diseases
    Journal Name: Trends in Biochemical Sciences
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.tibs.2020.12.003
    Citation Count: 2
  • Summary Details
    RESTRICTED
    Title: The protean roles of neuroinflammation in trauma, infections, autoimmunity and neurodegeneration
    Journal Name: Seminars in Immunology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.smim.2022.101655
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging
    Journal Name: Seminars in Arthritis and Rheumatism
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.semarthrit.2021.08.004
    Citation Count: 23
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.